Sanofi would be just fine without more M&A, chairman says

Sanofi ($SNY) Chairman Serge Weinberg says his company can do without dealmaking. And good thing, Weinberg told Les Echos--because the potential buys on the market are too expensive. "We … found the asking prices to be too high for the businesses," Weinberg told the French pub, adding that the company's balance of innovation and diversification "makes acquisitions not indispensable." Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.